secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001171843-22-007074
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Q3 net loss $14.8M; cash $49.6M, CPI-818 data at ASH
-----------------------------------------------------------

- Net loss $14.8M for Q3 2022 vs $10.7M Q3 2021; R&D expense $10.4M (+$3.4M).
- Cash, equivalents & securities $49.6M at Sep 30, 2022; projected year-end $40.5-42.5M.
- CPI-818 200 mg cohort: 1 CR lasting 25 months, 1 nodal CR 16 months, 1 PR; new data at ASH Dec 2022.
- Ciforadenant Phase 1b/2 in first-line RCC initiated with KCRC; up to 60 patients.
- IND approved in China for mupadolimab Phase 1/1b combo with pembrolizumab in lung/head & neck cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184322007074/0001171843-22-007074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184322007074/f8k_110322.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-007074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer